Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Tuesday April 04 2017, @11:54AM   Printer-friendly
from the high-cost-of-living? dept.

New cancer immunotherapies such as checkpoint inhibitors are showing success in treating cancer, but can cost well over $100,000 a year:

Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year.

The drugs' success for patients is the result of big bets in cancer therapy made by Bristol-Myers Squibb Co, Merck & Co Inc and Roche Holding AG, among others in big pharma. The industry's pipeline of cancer drugs expanded by 63 percent between 2005 and 2015, according to the QuintilesIMS Institute, and a good number are reaching the market.

The global market for cancer immunotherapies alone is expected to grow more than fourfold globally to $75.8 billion by 2022 from $16.9 billion in 2015, according to research firm GlobalData.

[...] "Competition is key to lowering drug prices," Trump told pharmaceutical executives at an Oval Office meeting in January.

But that is not happening with new drugs called checkpoint inhibitors that work by releasing a molecular brake, allowing the immune system to recognize and attack cancer cells the same way it fights infections caused by bacteria or viruses.

For cancers like melanoma, the treatments can mean long-term survival for around 20 percent of patients.

Bristol's Yervoy, first approved in 2011, targets a protein known as CTLA-4. Other immunotherapies, including Bristol's Opdivo, Keytruda from Merck, Roche's Tecentriq, and Pfizer Inc's Bavencio, involve a different protein called PD-1.

Other targets are being explored. Some new data will be presented this week in Washington at the American Association for Cancer Research's annual meeting.

Current checkpoint inhibitors each have a list price near $150,000 a year. A combination of Yervoy and Opdivo, approved by the Food and Drug Administration for advanced or inoperable melanoma, has a cost of $256,000 a year for patients who respond to the treatment.

Similar immunotherapies are in development at companies like AstraZeneca Plc (AZN.L). Merck, which declined to comment on pricing plans, expects an FDA decision by May 10 on its combination of Keytruda and chemotherapy as an initial treatment for the most common form of lung cancer - by far the biggest market for cancer drugs.

Pfizer said Bavencio, cleared by the FDA earlier this month to treat Merkel cell carcinoma, a rare type of skin cancer, has a price "comparable to other checkpoint inhibitors approved for different indications."


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 3, Insightful) by Dunbal on Tuesday April 04 2017, @03:12PM (1 child)

    by Dunbal (3515) on Tuesday April 04 2017, @03:12PM (#488650)

    Rubbish. Science is advanced by EDUCATION. Profit gets you the $600 epi pen. That doesn't work [usatoday.com].

    Starting Score:    1  point
    Moderation   +1  
       Insightful=1, Total=1
    Extra 'Insightful' Modifier   0  
    Karma-Bonus Modifier   +1  

    Total Score:   3  
  • (Score: 4, Insightful) by Thexalon on Tuesday April 04 2017, @03:30PM

    by Thexalon (636) on Tuesday April 04 2017, @03:30PM (#488655)

    I think you missed the joke, since both of the things the GP mentioned were government efforts.

    --
    The only thing that stops a bad guy with a compiler is a good guy with a compiler.